Streetbeat News

Analyst Ratings

FSLR

Truist Securities analyst Jordan Levy initiated coverage on First Solar, Inc. (NASDAQ:FSLR) with a Buy rating and a $300 price target. Levy highlights First Solar's competitive edge due to its technology, R&D investments, and contracted backlog. The company is expected to benefit from the push to onshore U.S. manufacturing and has a strong long-term growth profile despite market volatility.

Portfolio Pulse from Nabaparna Bhattacharya

September 26, 2024 | 6:13 pm

MU

Rosenblatt analyst Hans Mosesmann maintains a Buy rating on Micron Technology and raises the price target from $225 to $250.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:12 pm

META

Rosenblatt analyst Barton Crockett has maintained a Buy rating on Meta Platforms and raised the price target from $643 to $811, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:10 pm

CSD

FRNW

GEV

GE Vernova Inc. (NYSE:GEV) is expected to generate $2.5 billion in free cash flow by 2026, driven by energy transition trends. Truist Securities initiated coverage with a Buy rating and a $300 price target. The company is positioned for growth in the electrification segment and has been selected for a hydrogen project by the U.S. Department of Energy.

Portfolio Pulse from Lekha Gupta

September 26, 2024 | 6:08 pm

MKFG

Lake Street analyst Jacob Stephan has downgraded Markforged Holding (NYSE:MKFG) from a Buy to a Hold rating.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:06 pm

CVNA

Carvana (NYSE:CVNA) has received mixed analyst ratings over the last quarter, with a range of bullish to bearish sentiments. The average 12-month price target has increased by 20.02% to $161.32. Carvana's financial performance shows strong revenue growth and efficient cost management, but its high debt-to-equity ratio raises concerns.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:01 pm

MD

Analysts have varied opinions on Pediatrix Medical Group (NYSE:MD), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 21.37% to $10.62. Despite revenue growth, the company faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:01 pm

VRDN

Analysts have varied ratings for Viridian Therapeutics (NASDAQ:VRDN), with a majority being bullish. Recent price targets have increased, indicating positive sentiment. Despite financial challenges, analysts maintain optimistic ratings, suggesting potential growth.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

ABT

Analysts have provided mixed ratings for Abbott Laboratories (NYSE:ABT) over the past three months, with a range of bullish to indifferent opinions. The average 12-month price target has increased by 2.95% to $126.83. Abbott's financial performance shows strong net margins and efficient asset management, despite lower revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

NIO

Deep-pocketed investors are showing a bullish sentiment towards NIO, with significant options activity detected. The options market indicates a potential price range of $3.0 to $10.0 for NIO. Analysts have mixed ratings, with price targets ranging from $5 to $8.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm